EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Application Value of In-House HIV-1 DNA Genotypic Resistance Testing for Individuals with Low-Level Viremia

Ying Zhou iD, Chuanfeng Zhang, Qi Sun, Tao Qiu, Qianjin Fan, Jing Lu, Haiyang Hu iD, Xiaoqin Xu, Dandan Yang, Haitao Yang

Viruses · 2026

DOI: 10.3390/v18101098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Ying Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of HIV/STD Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. Hauptthemen laut MEDLINE: HIV-1, Viremia, Drug Resistance, Viral, HIV Infections. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Provincial Disease Control and Prevention Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To provide evidence for HIV-1 DNA genotypic resistance testing (GRT) strategies in low-level viremia (LLV) populations by comparing the amplification efficiency and resistance mutation profiles between HIV-1 DNA GRT and RNA GRT. (2)

Methods

Convenience sampling was used for participant enrolment. Plasma HIV-1 RNA and peripheral blood monocyte (PBMC) DNA were extracted separately. The protease–reverse transcriptase (PR-RT) region was amplified via an in-house protocol, followed by Sanger and Nanopore sequencing. The exact McNemar’s test and Fisher’s test were applied to compare amplification success rates. Univariate and multivariable logistic regression analyses implemented in R were conducted to identify factors associated with the detection of HIV-1 drug-resistant strains. BEAST-based molecular clock analysis was performed to calculate the divergence time between RNA-derived and DNA-derived sequences. (3)

Results

A total of 209 samples were enrolled, and valid sequences were obtained from 166 samples. Within the viral load range of 50–200 copies/mL, HIV-1 DNA GRT yielded significantly higher amplification success rates than RNA GRT (p < 0.05). The overall resistance detection rate for DNA GRT (20.8%) was lower than that for RNA GRT (33.7%), with discrepancies mainly involving nucleoside reverse transcriptase inhibitor (NRTI)- and non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated mutations. Individuals receiving antiretroviral therapy (ART) for 7–18 months exhibited higher odds of detecting drug-resistant strains using either DNA GRT or RNA GRT. The median evolutionary divergence time between matched RNA- and DNA-derived sequences was 3.13 years. By contrast, the median evolutionary divergence time between paired DNA generated by Sanger and Nanopore sequencing was 0.84 years. (4)

Conclusions

DNA GRT serves as a valuable supplementary screening tool in public health scenarios of LLV with failed RNA GRT amplification. However, clinical interpretation should combine RNA GRT findings, longitudinal viral load monitoring and treatment history, rather than relying solely on DNA GRT to modify antiretroviral regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1ViremiaDrug Resistance, ViralHIV InfectionsDNA, ViralHumansGenotypeFemaleRNA, ViralMutationAnti-HIV AgentsViral LoadMaleAdult

Stichwörter der Autor:innen

DNA genotypic drug resistance testingHIV-1evolutionary divergence time

Substanzen

DNA, ViralRNA, ViralAnti-HIV Agents

Autor:innen und Institutionen

  • Department of HIV/STD Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.

ORCID-Profile: Ying Zhou, Haiyang Hu

Förderung

  • Jiangsu Provincial Disease Control and Prevention Administration

Zitieren

APA

Zhou, Y., Zhang, C., Sun, Q., Qiu, T., Fan, Q., Lu, J., Hu, H., Xu, X., Yang, D., & Yang, H. (2026). Application Value of In-House HIV-1 DNA Genotypic Resistance Testing for Individuals with Low-Level Viremia. Viruses. https://doi.org/10.3390/v18101098

Vancouver

Zhou Y, Zhang C, Sun Q, Qiu T, Fan Q, Lu J, et al. Application Value of In-House HIV-1 DNA Genotypic Resistance Testing for Individuals with Low-Level Viremia. Viruses. 2026. doi:10.3390/v18101098

BibTeX
@article{Zhou2026,
  author = {Zhou, Ying and Zhang, Chuanfeng and Sun, Qi and Qiu, Tao and Fan, Qianjin and Lu, Jing and Hu, Haiyang and Xu, Xiaoqin and Yang, Dandan and Yang, Haitao},
  title = {Application Value of In-House HIV-1 DNA Genotypic Resistance Testing for Individuals with Low-Level Viremia},
  journal = {Viruses},
  year = {2026},
  doi = {10.3390/v18101098}
}
Kostenlos starten →